Personalised Follow-up of QOL in longitudinal studies: the example of promising experimental treatment of recurrent glioblastoma with avelumab and axitinib

Research output: Chapter in Book/Report/Conference proceedingMeeting abstract (Book)

Abstract

Background
Follow-up of subjective QOL in longitudinal interventional studies, clinical or societal, is imperative but challenging because of relativity biases, including changing frame of reference in the self-assessment due to response shift. Glioblastoma, the most frequent malignant tumor of the brain hitherto almost invariably recurs after surgery, chemotherapy and radiation therapy. Recurrent glioblastoma (recGB) entails a median survival of 25-30 weeks. A new treatment with axitinib and avelumab is anticipated to be highly effective.
Method
Together with medical-oncological follow-up, the QOL of experimentally treated patients with recGB is recorded at week 9 and every 12 weeks after baseline. The standard multi-dimensional EORTC Quality of Life Questionnaire (QLQ-C30) is complemented by the Anamnestic Comparative Self-Assessment (ACSA), a personalised unisclale of global SWB in which the +5 and -5 scale anchors are defined by the respondents as equivalent to respectively the best and the worst periods in their life experience. ACSA thus has a potential to circumvent response shift.
Results
Of this ongoing study we have at time of writing for 29 patients baseline results, i.e. before start of treatment for recGB. The QLQ-C30 shows high rates of fatigue (M = 55.56, SD = 26.19), less insomnia (M = 29.63, SD = 33.76), elevated emotional functioning (M = 65.18, SD = 31.35) and diminished global health (M = 48.77, SD = 23.54). The ACSA score at baseline is highly variable, with mean close to equipoise between good and bad (M = 0.38, SD = 3.02).
Discusssion
We hope to present follow-up results.
Original languageEnglish
Title of host publicationPersonalised Follow-up of QOL in longitudinal studies: the example of promising experimental treatment of recurrent glioblastoma with avelumab and axitinib
Publication statusPublished - 13 Jun 2018

Keywords

  • Subjective Quality Of Life
  • Glioblastoma
  • Axitinib
  • Avemulab

Fingerprint

Dive into the research topics of 'Personalised Follow-up of QOL in longitudinal studies: the example of promising experimental treatment of recurrent glioblastoma with avelumab and axitinib'. Together they form a unique fingerprint.

Cite this